Targovax ASA: Poster at European Society for Medical Oncology (ESMO)

OSLO, Norway, Sept. 16, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that the poster "A pilot study of Engineered Adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma" is now available at the ESMO congress website and on the Company's website.  The poster will be presented as an e-poster at the European Society for Medical Oncology (ESMO) congress by Dr Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center.